Neox Clinical Research, a Czech-based CRO, is pleased to announce they will be opening an office in San Diego, California in the first quarter of 2012 as their North American headquarters.
"Opening an office in the United States is a natural geographic addition for our overall global growth strategy. As we continue to add clients, backlog, feature sets and staff in the US it was an easy choice for us to open an office in San Diego," said Pavel Marek MD, CEO, Neox.
Heading up the US operations is Matt Delaney, Managing Director, Neox US Matt is an industry executive with more than 25 years of experience. Matt was previously Vice President of worldwide sales and marketing for a mid-size global CRO. "We are delighted to have Matt join the Neox team. Matt's experience in building and managing regions and teams will be a key ingredient for Neox's overall success", said Pavel Marek.
Neox also strengthens its management team in Europe. Jennifer Haggard, MS, has been hired to act as the Managing Director of Neox Europe. She is strategically located in a newly opened Neox office in Aachen, Germany. Jen has a long-lasting experience from both CRO and Pharma industries. "I believe that Jen is the key person for the overall management of European operations", said Pavel Marek. "I am delighted to be a part of the Neox team. Our experience conducting trials in CEE countries is significant and further expansion throughout Europe is paramount for Neox," Jen stated.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.